PRECISE Consortium Launches to Build Predictive Cancer Vulnerability Maps Across Europe
核心洞察
The PRECISE consortium (搜索) unites over 30 research groups from 20+ institutes across nine European countries to advance cancer vulnerability prediction.
Unlike existing cancer dependency maps, PRECISE will use an iterative prediction-validation approach combining functional genomics, multimodal profiling, and artificial intelligence.
The initiative aims to develop generalizable rules for anticipating cancer vulnerabilities across tumor types, expanding precision oncology to patients lacking actionable treatment options.
A major European collaboration formally launched this month aims to transform how researchers identify and predict cancer vulnerabilities, moving beyond descriptive dependency maps toward true predictive modeling. The PRECISE consortium (搜索)—short for Predictive Relationships Explaining Cancer Genetic Interactions and Synthetic Essentiality—brings together more than 30 experimental and computational research groups from over 20 institutes and universities across nine European countries, with its vision outlined in a Nature Genetics commentary.
At the MRC Weatherall Institute of Molecular Medicine (搜索), Dr. Sumana Sharma is among the researchers contributing to the consortium's ambitious agenda.
"This is an exciting time for cancer vulnerability prediction," Sharma said. "We are moving beyond simple growth-based assessments towards a deeper understanding of context-specific dependencies that drive tumour biology. International collaborations such as the PRECISE consortium (搜索) are essential for accelerating this shift, enabling us to identify and target cancer vulnerabilities from the outset through the integration of expertise, data, and technologies across Europe."
An Iterative Prediction-Validation Framework
Unlike existing cancer dependency maps, which largely describe vulnerabilities that have already been observed, PRECISE will deploy an iterative prediction-validation approach. Computational models will guide laboratory experiments, with the resulting data feeding back into improved predictions. The consortium will combine functional genomics, multimodal molecular profiling, and artificial intelligence to build predictive models that explain why cancers become dependent on particular genes or pathways.
The long-term goal is to develop generalizable rules that can anticipate cancer vulnerabilities across different tumor types and biological contexts. This capability could ultimately help expand precision oncology to patients whose cancers currently lack actionable treatment options—a persistent gap in the oncology landscape.
Commitment to Open Science
PRECISE is also structured around open science principles. The consortium promotes common experimental standards, interoperable analytical pipelines, and FAIR (Findable, Accessible, Interoperable and Reusable) data principles to ensure that datasets and computational tools can be shared, integrated, and reused across the international research community. This infrastructure is designed to accelerate discovery beyond the consortium's own laboratories, enabling broader scientific engagement with cancer vulnerability data.
The initiative represents a significant step toward a future where cancer dependencies can be predicted rather than merely catalogued, potentially unlocking new therapeutic opportunities in previously untested settings and broadening the reach of precision oncology.